Brazilian researchers at the University of São Paulo (USP) have made a groundbreaking discovery in the fight against triple-negative breast cancer (TNBC), one of the most aggressive forms of the disease. A natural compound called cephalochromin, isolated from an endophytic fungus living within leaves of the Atlantic Forest plant Moquiniastrum polymorphum, shows potent anti-cancer activity and enhances the effectiveness of standard chemotherapy drugs. Published in the prestigious Journal of Natural Products, this finding highlights USP's leadership in natural products research and bioprospecting from Brazil's rich biodiversity.
TNBC accounts for 15-20% of breast cancers and lacks targeted therapies due to the absence of estrogen, progesterone, and HER2 receptors, making it reliant on chemotherapy with high recurrence rates. Survivin (BIRC5), a protein overexpressed in TNBC cells, inhibits apoptosis and promotes resistance. Cephalochromin's ability to target survivin offers a promising avenue for new treatments.
The Unique Source: Endophytic Fungi in Atlantic Forest Leaves
Endophytic fungi are microorganisms that live inside plant tissues without causing harm, often producing bioactive compounds as defense mechanisms. The fungus Alternaria sp. was isolated from healthy leaves of Moquiniastrum polymorphum, an Asteraceae species native to Brazil's Atlantic Forest, a biodiversity hotspot covering São Paulo and surrounding regions.
Researchers from USP's Department of Botany collected the plant (voucher Farinella 02) and cultured the fungus on potato dextrose agar (PDA) at 25°C for 60 days. Extraction with ethyl acetate, followed by purification via semipreparative HPLC, yielded pure cephalochromin. Its structure was confirmed by NMR spectroscopy, matching known spectra with characteristic phenolic OH groups and carbonyls.
This approach exemplifies how Brazil's universities leverage endemic flora for drug discovery, preserving biodiversity while advancing pharmacology.
Meet the USP Research Team Behind the Breakthrough
Lead author Isabelle Diccini, a master's student in Pharmacology at USP's Instituto de Ciências Biomédicas (ICB-USP), conducted the experiments under supervisor João Agostinho Machado-Neto, PhD from the Department of Pharmacology. The team includes Natália Sudan Parducci, Bruna Oliveira de Almeida, Victor Farinella (Botany, IB-USP), Patrick Castilho dos Santos, Livia Bassani Lins de Miranda, Sabrina Mendes Botelho (São Carlos Institute of Chemistry), Keli Lima, Jorge Antonio Elias Godoy Carlos, Anali Del Milagro Bernabe Garnique, Marcelo José Pena Ferreira (Botany), Leticia Veras Costa-Lotufo, all affiliated with USP.
"Using lower concentrations of drugs can generate fewer adverse effects because it potentiates the therapeutic effect without necessarily increasing toxicity," Machado-Neto explained. Diccini added, "An effective treatment for such an aggressive subtype could mean lower doses, fewer side effects, and better quality of life for patients."
USP's collaborative model across departments underscores its role as Brazil's premier research institution. For aspiring researchers, explore research jobs or faculty positions at USP-like institutions.
Methodology: Rigorous In Vitro Testing Protocols
The study employed standard oncology assays: MTT for cytotoxicity (IC50 determination), colony formation for clonogenic survival, flow cytometry for cell cycle (propidium iodide) and apoptosis (annexin V/PI), Western blot for proteins (PARP1, γH2AX, survivin, SQSTM1/p62, LC3B), qRT-PCR for 22 genes, and combination index analysis (ZIP score) with paclitaxel and doxorubicin.
- Test cell lines: TNBC (MDA-MB-231, Hs578T, MDA-MB-468), non-TNBC (MCF-7, SK-BR-3), nonmalignant MCF-10A.
- Doses: 0.1–10 μM cephalochromin, 24–72h exposure.
- Combinations: Fixed ratios, Chou-Talalay method.
These methods ensure reproducibility and clinical relevance.
Key Findings: Potent Cytotoxicity and Apoptosis Induction
Cephalochromin exhibited IC50 values of 0.6–1.6 μM in TNBC lines, 5–13 μM in non-TNBC, and >10 μM in healthy cells, showing selectivity. It inhibited colony formation by 80-90% and induced G2/M arrest/subG1 accumulation.
Apoptosis was confirmed by PARP1 cleavage, annexin V positivity (up to 60%), and downregulation of survivin (BIRC5). DNA damage markers (γH2AX) increased, alongside autophagy indicators (LC3BII, SQSTM1/p62), suggesting autophagic catastrophe.
Gene expression heatmap revealed modulation of apoptosis (CASP3 up), DNA repair (GADD45A up), and autophagy pathways.
Synergistic Effects with Chemotherapy Drugs
In combination studies, cephalochromin synergized with doxorubicin (ZIP score >10) and was additive with paclitaxel (ZIP >5), reducing IC50 and allowing lower chemo doses. This chemosensitization targets survivin-mediated resistance, a major TNBC challenge.
Clinical implication: Reduced toxicity, better patient tolerance. For Brazilian pharma researchers, this opens doors—check Brazil higher ed jobs.
Safety Profile and Selectivity for Cancer Cells
Unlike many cytotoxics, cephalochromin spared MCF-10A cells (IC50 >20 μM), a key advantage. No significant genotoxicity in healthy lines, positioning it as a selective agent.
Targeting Survivin: A Novel Mechanism in TNBC
Survivin overexpression correlates with poor TNBC prognosis. Cephalochromin reduced BIRC5 mRNA/protein, activating caspase cascade. Multi-pathway action (apoptosis, autophagy, DNA damage) minimizes resistance risk vs. single-target drugs.
Implications for Triple-Negative Breast Cancer Treatment
TNBC has 5-year survival ~77%, worse in Brazil due to late diagnosis. Cephalochromin could complement neoadjuvant therapy, improving pathologic complete response rates. Synergy reduces chemo doses by 50-75%, cutting cardiotoxicity from doxorubicin.
In Brazil, where TNBC incidence rises, USP's work advances national health goals. Link: Full paper in Journal of Natural Products
USP's Excellence in Natural Products and Bioprospecting
USP leads Brazil's natural products research, with ICB and IQSC hubs screening fungal/plant metabolites. Past successes include spiroxin A. FAPESP funding supports this, fostering PhD/master's training. Brazil's 20% global biodiversity fuels such discoveries.
Explore USP careers via university jobs.
Brazilian Biodiversity: A Goldmine for Drug Discovery
Atlantic Forest hosts 20,000 plants, many endophyte-rich. Brazil contributes 70,000 natural products studies globally. Policies like Nagoya Protocol ensure equitable bioprospecting. USP exemplifies higher ed's role in sustainable innovation.
Future Outlook: From Lab to Clinic
Next: In vivo xenograft models, pharmacokinetics. Clinical trials (10+ years away) could yield TNBC adjuvant. Partnerships with pharma vital. USP's pipeline promises more.USP news
Photo by National Cancer Institute on Unsplash
Brazilian Higher Education's Role in Global Health Innovation
USP ranks top Latin America, producing 25% national papers. Investments in biotech (R$10B+ CNPq/FAPESP) drive this. For students/professors, opportunities abound in higher ed career advice.
In conclusion, cephalochromin exemplifies USP's impact. Stay updated on research jobs at higher-ed-jobs, rate professors at rate-my-professor, or explore university jobs in Brazil.